Alexis Cortot, Centre Hospitalier Universitaire de Lille (CHU Lille), France, discusses the current clinical practice for the management of patients with METex14 non-small cell lung cancer (NSCLC) with Keith Kerr, Aberdeen University Medical School, UK, and Maximilian Hochmair, Klinik Floridsdorf, Vienna, Austria. Focusing on real-world evidence and their role in clinical practice, the experts address safety data from clinical trials. They also review the current and future treatment options for METex14 NSCLC, while highlighting challenges that are associated with identifying MET mutations.
This content has been funded by Novartis, however, the position and discussions might not represent the position of Novartis. The content is intended for non-USA and non-UK healthcare professionals.
